📗 Cite This Artifact
Eli Lilly and Company — Neuroscience and Tauopathy Programs
Eli Lilly and Company
Path: /companies/eli-lilly Status: Public (NYSE: LLY) Headquarters: Indianapolis, Indiana, USA Founded: 1876 CEO: David A. Ricks Market Cap: ~$800B (2025) Website: [lilly.com](https://www.lilly.com)
Overview
Eli Lilly and Company is one of the world's largest pharmaceutical companies, with a significant investment in neuroscience and neurodegenerative disease therapeutics. The company gained a leading position in the tauopathy space through its acquisition of Swiss biotech Asceneuron in 2023, adding OGA inhibitors to its pipeline.
Neuroscience Focus
Lilly's neuroscience division has grown to become one of its highest-priority therapeutic areas:
Current Pipeline
| Drug | Mechanism | Indication | Stage |
|------|----------|-----------|--------|
| Zaniglusemab (LY3372689) | OGA inhibitor | PSP | Phase 2 (LOTUS) |
| Zaniglusemab (LY3372689) | OGA inhibitor | AD (MAGNOLIA) | Phase 2 |
| Remternetug | Anti-tau antibody | AD | Phase 3 |
| LY3891044 | Tau aggregation inhibitor | Preclinical | Research |
PSP Program: Zaniglusemab (LY3372689)
Background
Zaniglusemab (formerly ASN90) is an O-GlcNAcase (OGA) inhibitor developed by Asceneuron and acquired by Lilly in 2023. The drug targets tau pathology by reducing tau hyperphosphorylation through O-GlcNAc modification.
Development Timeline
...
Eli Lilly and Company
Path: /companies/eli-lilly Status: Public (NYSE: LLY) Headquarters: Indianapolis, Indiana, USA Founded: 1876 CEO: David A. Ricks Market Cap: ~$800B (2025) Website: [lilly.com](https://www.lilly.com)
Overview
Eli Lilly and Company is one of the world's largest pharmaceutical companies, with a significant investment in neuroscience and neurodegenerative disease therapeutics. The company gained a leading position in the tauopathy space through its acquisition of Swiss biotech Asceneuron in 2023, adding OGA inhibitors to its pipeline.
Neuroscience Focus
Lilly's neuroscience division has grown to become one of its highest-priority therapeutic areas:
Current Pipeline
| Drug | Mechanism | Indication | Stage |
|------|----------|-----------|--------|
| Zaniglusemab (LY3372689) | OGA inhibitor | PSP | Phase 2 (LOTUS) |
| Zaniglusemab (LY3372689) | OGA inhibitor | AD (MAGNOLIA) | Phase 2 |
| Remternetug | Anti-tau antibody | AD | Phase 3 |
| LY3891044 | Tau aggregation inhibitor | Preclinical | Research |
PSP Program: Zaniglusemab (LY3372689)
Background
Zaniglusemab (formerly ASN90) is an O-GlcNAcase (OGA) inhibitor developed by Asceneuron and acquired by Lilly in 2023. The drug targets tau pathology by reducing tau hyperphosphorylation through O-GlcNAc modification.
Development Timeline
| Milestone | Date | Notes |
|----------|------|------|
| Discovery | 2015-2019 | Asceneuron OGA inhibitor program |
| Phase 1 | 2020 | Safety, PK, CSF target engagement |
| Phase 2 AD (MAGNOLIA) | 2021-2024 | Early AD, biomarker effects confirmed |
| Lilly Acquisition | 2023 | $60M upfront + milestones |
| Phase 2 PSP (LOTUS) | 2022-Present | First OGA inhibitor in PSP |
| Expected Results | Q4 2026 | LOTUS primary endpoint |
LOTUS Trial (NCT05433740)
LOTUS (Lyming OGA inhibitor Trial in PSP) is the pivotal Phase 2 study:
- Design: Randomized, double-blind, placebo-controlled
- Enrollment: ~200 patients with PSP
- Primary Endpoint: change in PSP Rating Scale (PSPRS)
- Secondary Endpoints: CSF O-GlcNAc, neuroimaging, cognition
MAGNOLIA Trial (AD)
The MAGNOLIA Phase 2 study in early Alzheimer's disease:
- Results: Biomarker effects (CSF tau reduction) confirmed
- Outcome: Did not meet primary cognitive endpoint
- Biomarker findings: Validated target engagement
Mechanism of Action
O-GlcNAcase Inhibition
Zaniglusemab works by inhibiting O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modifications from proteins:
- Tau hyperphosphorylation: Reduced O-GlcNAc leads to increased tau phosphorylation
- OGA inhibition: Increases tau O-GlcNAcylation, reducing hyperphosphorylation
- Aggregation prevention: Modified tau less likely to form aggregates
Rationale for PSP
PSP and other 4R-tauopathies show:
- Tau aggregation: 4R tau forms insoluble aggregates
- OGA activity: Elevated OGA in tauopathies
- Therapeutic angle: OGA inhibition may slow aggregation
Corporate Strategy
Acquisition of Asceneuron
The 2023 acquisition of Asceneuron reflects Lilly's tauopathy strategy:
- Strategic rationale: Add OGA inhibitor platform
- Complementary to remternetug: Antibody + small molecule tau approach
- Swiss presence: Basel neuroscience research site
- Team retention: Key Asceneuron scientists joined Lilly
Portfolio Approach
Lilly is pursuing a multi-mechanism tau strategy:
Financial Impact
Pipeline Investment
Lilly's neuroscience investment:
- R&D: ~$8B annually (all programs)
- Tauopathy programs: Significant portion of neuroscience budget
- Acquisition cost: $60M upfront (Asceneuron)
Market Position
The tauopathy market represents significant opportunity:
- PSP: ~$1B potential peak sales
- AD: >$10B potential
- Competitive landscape: Multiple mechanisms in development
Partnerships
Academic Collaborations
- University of Pennsylvania: Biomarker development
- UCL Institute of Neurology: Clinical trial site
- Mayo Clinic Florida: PSP expertise
Industry Partnerships
- CurePSP: Clinical trial promotion
- Coalition for 4R-Tau: Industry consortium
Cross-References
- [Asceneuron](/researchers/asceneuron) — Acquired biotech
- [OGA Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape)
- [LY3372689 PSP Trial](/clinical-trials/ly3372689-lotus-psp)
- [CurePSP](/organizations/curepsp) — Trial sponsor
- [4R-Tauopathies](/mechanisms/4r-tauopathies)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-eli-lilly |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-4b5cb2fd2008 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-eli-lilly'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-eli-lilly?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Eli Lilly and Company — Neuroscience and Tauopathy Programs](http://scidex.ai/artifact/wiki-companies-eli-lilly)
http://scidex.ai/artifact/wiki-companies-eli-lilly